Publications by authors named "David Moura"

Claim this Profile
S
Spatial immunoprofiling of retroperitoneal leiomyosarcomas reveals intratumoral heterogeneity in immune cell infiltration, checkpoint molecule expression, and tertiary lymphoid structures.
Iva Benesova, Jan Balko, Vira Tovazhnianska, Michal Rataj, Robert Lischke, David Moura

Ann Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of BET inhibitors (BETi) against solitary fibrous tumor (SFT) through high-throughput screening (HTS).
Jose L Mondaza-Hernandez, David S Moura, Yi Li, Jesus L Marti, Paulino Gomez-Puertas

Neoplasia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histopathologic Diagnostic Agreement Study in Bone and Soft Tissue Tumors: The SELNET Sarcoma Network Experience.
Alberto Righi, Marco Gambarotti, Rafael Ramos, Rodolfo Guzman, Carmen Nieves Hernandez-Leon, David S Moura

JCO Glob Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomics-led approach to drug testing in models of undifferentiated pleomorphic sarcoma.
Piotr J Manasterski, Molly R Danks, John P Thomson, Morwenna Muir, Martin Lee, David S Moura

Mol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common Peroneal Nerve Palsy Due to a Proximal Tibiofibular Joint Ganglion Cyst in a Recreational Runner: A Case Report.
Luís Amaral Oliveira, Ana Margarida Esteves, Bruno Cancela, David Moura, Rodrigo Correia

Cureus· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Which sarcoma requires PD1/PDL1 inhibitors, and what should be the best scheme? Present status and next steps.
Javier Martin-Broto, David S Moura, Nadia Hindi

Curr Opin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical models of soft tissue sarcomas - generation and applications to enhance translational research.
Sandro Pasquali, David S Moura, Molly R Danks, Piotr J Manasterski, Nadia Zaffaroni

Crit Rev Oncol Hematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of BET Inhibitors (BETi) Against Solitary Fibrous Tumor (SFT) Through High-Throughput Screening (HTS).
Jose L Mondaza-Hernandez, David S Moura, Yi Li, Jesus Lopez-Marti, Paulino Gomez-Puertas

bioRxiv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS).
Javier Martin-Broto, Roberto Diaz-Beveridge, David Moura, Rafael Ramos, Javier Martinez-Trufero

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial.
Emanuela Palmerini, Antonio Lopez Pousa, Giovanni Grignani, Andres Redondo, Nadia Hindi, David S Moura

Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial.
David S Moura, Jesus M Lopez-Marti, Iva Benesova, Carlos de Andrea, Davide di Lernia

Clin Cancer Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcoma.
José L Mondaza-Hernandez, Nadia Hindi, Antonio Fernandez-Serra, Rafael Ramos, Ricardo Gonzalez-Cámpora, David S Moura

Ther Adv Med Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor.
Jaime Carrillo-García, Nadia Hindi, Magda Conceicao, María Ángeles Sala, Aitziber Ugalde, David S Moura

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shared germline genomic variants in two patients with double primary gastrointestinal stromal tumours (GISTs).
David S Moura, Daniel López López, Davide di Lernia, Marta Martin-Ruiz, Maria Lopez-Alvarez

J Med Genet· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination treatment with PD1/PDL-1 inhibitors for sarcomas: state of the art, next questions.
Javier Martin-Broto, Nadia Hindi, David S Moura

Curr Opin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STAT6-targeting antisense oligonucleotides against solitary fibrous tumor.
Yi Li, Jose L Mondaza-Hernandez, David S Moura, Alexey S Revenko, Angelica Tolentino

Mol Ther Nucleic Acids· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best Overall Response-Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE.
Jiangang Liu, David S Moura, Robin L Jones, Amit Aggarwal, Philip J Ebert

Clin Cancer Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating TNF-RII, IP-10 and HGF are associated with severity of COVID-19 in oncologic patients.
Jaime Carrillo-García, Serena Lacerenza, Nadia Hindi, David S Moura, Gloria Marquina

Cytokine· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.
David S Moura, Jose L Mondaza-Hernandez, Paloma Sanchez-Bustos, Maria Peña-Chilet, Juan A Cordero-Varela

Cell Mol Life Sci· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain.
Jaime Carrillo-García, Serena Lacerenza, Nadia Hindi, Irene Carrasco García, Gloria Marquina, David S Moura

Ther Adv Med Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma.
Javier Martin-Broto, Alicia Olarte-García, Ricardo Fernandéz-Rodríguez, Marta Ribeiro Ferreira, Irene Carrasco-García, David S Moura

Ther Adv Med Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A.
Javier Martin-Broto, Jeronimo Martinez-Garcia, David S Moura, Andres Redondo, Antonio Gutierrez

Signal Transduct Target Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiangiogenics in Malignant Granular Cell Tumors: Review of the Literature.
Carlos Torrado, Melisa Camaño, Nadia Hindi, Justo Ortega, Alberto R Sevillano, David S Moura

Cancers (Basel)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oromandibular Dystonia as a Side Effect of Methotrexate.
Diana Oliveira, David Moura, Sofia Azevedo, Bruno Guimarães, Sofia Toste

Cureus· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.
Javier Martin-Broto, Claudia Valverde, Nadia Hindi, Bruno Vincenzi, Javier Martinez-Trufero, David S Moura

Mol Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis